Clinical Trial

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage…

1 year ago

WCG Releases 2024 Report on Top Issues Impacting Clinical Research Sites

PRINCETON, N.J., Oct. 8, 2024 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve the quality and…

1 year ago

UFC’s Michael Chandler Joins “Official UFC Partner” Aires Tech To Champion EMF Protection As Brand Partner

Chandler strengthens the #AiresAthletes campaign, reinforcing the importance of EMF protection to enhance recovery and overall well-being*Chandler fuels Aires' brand…

1 year ago

Florence Healthcare Partners with ScienceMedia to Ease Training Burden for Clinical Sites

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- ScienceMedia, a global SaaS clinical trial training solution provider, and Florence Healthcare, the…

1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT /…

1 year ago

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA

TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…

1 year ago

Parexel’s Teri Karcher Named to 2024 PharmaVoice 100

Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development DURHAM,…

1 year ago

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing…

1 year ago

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to…

1 year ago